Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. et al, No. 2:15-cv-01455 (E.D. Tex. Jan. 12, 2017)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

B efore the Court is the motion of defendant Teva Pharmaceuticals USA, Inc., (“Teva”) to amend its answer and counterclaims to raise the issues of inequitable conduct and unclean hands. Dkt. No. 189. The motion was briefed by the parties and argued during a telephonic hearing conducted on January 11, 2017. The Court DENIES the motion. BACKGROUND This case was filed on August 15, 2015. Dkt. No. 1. Teva filed its original answer and counterclaims on October 26, 2015. Dkt. No. 40.